Cancer Cell Biology

You have full text access to this OnlineOpen article

Lef-1 isoforms regulate different target genes and reduce cellular adhesion

  1. Sarah Jesse1,†,
  2. Alexander Koenig1,2,†,
  3. Volker Ellenrieder2,
  4. Andre Menke1,‡,*

Article first published online: 3 AUG 2009

DOI: 10.1002/ijc.24802

Issue

International Journal of Cancer

International Journal of Cancer

Volume 126, Issue 5, pages 1109–1120, 1 March 2010

Additional Information

How to Cite

Jesse, S., Koenig, A., Ellenrieder, V. and Menke, A. (2010), Lef-1 isoforms regulate different target genes and reduce cellular adhesion. Int. J. Cancer, 126: 1109–1120. doi: 10.1002/ijc.24802

Author Information

  1. 1

    Department of Internal Medicine I, University of Ulm, D-89081 Ulm, Germany

  2. 2

    Department of Gastroenterology and Endocrinology, University Hospital Giessen and Marburg, D-35033 Marburg, Germany

  1. †

    The first two authors contributed equally to this work

  2. ‡

    Tel.: 0731/500 44678, Fax: 0731/500 45216

*Department of Internal Medicine I, University of Ulm, D-89081 Ulm, Germany

Publication History

  1. Issue published online: 27 DEC 2009
  2. Article first published online: 3 AUG 2009
  3. Accepted manuscript online: 3 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 23 JUL 2009
  5. Manuscript Received: 28 OCT 2008

Funded by

  • The Deutsche Forschungsgemeinschaft. Grant Number: SFB 518, B4
  • The MD program of the medical faculty of the University Ulm

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (652K)

References

  • 1
    Murakami T, Toda S, Fujimoto M, Ohtsuki M, Byers HR, Etoh T, Nakagawa H. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys. Res Commun 2001; 288: 8–15.
  • 2
    Waterman ML. Expression of lymphoid enhancer factor/T-cell factor proteins in colon cancer. Curr Opin Gastroenterol 2002; 18: 53–59.
  • 3
    Wang W, Ji P, Steffen B, Metzger R, Schneider PM, Halfter H, Schrader M, Berdel WE, Serve H, Muller-Tidow C. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. Acta Biochim Biophys Sin (Shanghai) 2005; 37: 173–180.
  • 4
    Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837–51.
  • 5
    Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469–80.
  • 6
    Hovanes K, Li TW, Waterman ML. The human LEF-1 gene contains a promoter preferentially active in lymphocytes and encodes multiple isoforms derived from alternative splicing. Nucleic Acids Res. 2000; 28: 1994–2003.
  • 7
    He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da CL, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509–12.
  • 8
    Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422–6.
  • 9
    Gradl D, Kühl M, Wedlich D. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol. Cell Biol. 1999; 19: 5576–87.
  • 10
    Giese K, Kingsley C, Kirshner JR, Grosschedl R. Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev 1995; 9: 995–1008.
  • 11
    Nawshad A, LaGamba D, Polad A, Hay ED. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 2005; 179: 11–23.
  • 12
    Daniels DL , Weis WI. Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 2005; 12: 364–71.
  • 13
    Arce L, Yokoyama NN, Waterman ML. Diversity of LEF/TCF action in development and disease. Oncogene 2006; 25: 7492–504.
  • 14
    Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat.Genet. 1998; 19: 379–83.
  • 15
    Wong NA, Pignatelli M. Beta-catenin–a linchpin in colorectal carcinogenesis? Am J Pathol 2002; 160: 389–401.
  • 16
    Merrill BJ, Pasolli HA, Polak L, Rendl M, Garcia-Garcia MJ, Anderson KV, Fuchs E. Tcf3: a transcriptional regulator of axis induction in the early embryo. Development 2004; 131: 263–74.
  • 17
    Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 2005; 19: 877–90.
  • 18
    Hennig G, Behrens J, Truss M, Frisch S, Reichmann E, Birchmeier W. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 1995; 11: 475–84.
  • 19
    Schneider G, Oswald F, Wahl C, Greten FR, Adler G, Schmid RM. Cyclosporine inhibits growth through the activating transcription factor/cAMP-responsive element-binding protein binding site in the cyclin D1 promoter. J Biol Chem 2002; 277: 43599–607.
  • 20
    Chen CR, Kang Y, Massague J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proceedings of the National Academy of Sciences 2001; 98: 992–9.
  • 21
    Seidel B, Braeg S, Adler G, Wedlich D, Menke A. E- and N-cadherin differ with respect to their associated p120(ctn) isoforms and their ability to suppress invasive growth in pancreatic cancer cells. Oncogene 2004; 23: 5532–42.
  • 22
    Bussemakers MJ, Giroldi LA, van Bokhoven A, Schalken JA. Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter. Biochem Biophys Res Commun 1994; 203: 1284–90.
  • 23
    Vogelmann R, Nguyen-tat MD, Giehl K, Adler G, Wedlich D, Menke A. TGFβ-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci 2005; 118: 4901–12.
  • 24
    Voisard R, Gecguner L, Baur R, Herter T, Hombach V. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio. Int J Cardiol 2005; 102: 435–42.
  • 25
    Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE. Molecular pathology of pancreatic cancer. Cancer J 2001; 7: 251–8.
  • 26
    Nawshad A, Medici D, Liu CC, Hay ED. TGFbeta3 inhibits E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4-LEF1 transcription complex. J Cell Sci 2007; 120: 46–53.
  • 27
    Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003; 116: 499–511.
  • 28
    Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia DH. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000; 2: 84–89.
  • 29
    Peinado H, Marin F, Cubillo E, Stark HJ, Fusenig N, Nieto MA, Cano A. Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J Cell Sci 2004; 117: 2827–39.
  • 30
    Conacci-Sorrell ME, Ben Yedidia T, Shtutman M, Feinstein E, Einat P, Ben Ze'ev A. Nr-CAM is a target gene of the beta -catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16: 2058–72.
  • 31
    Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155: 1033–8.
  • 32
    Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y. Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol.Res 2001; 12: 469–76.
  • 33
    Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003; 83: 337–76.
  • 34
    Kyriazis AA, Kyriazis AP, Sternberg CN, Sloane NH, Loveless JD. Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse. Cancer Res 1986; 46: 5810–15.
  • 35
    Tan MH, Chu TM. Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour Biol 1985; 6: 89–98.
  • 36
    Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian R, Douglass HO,Jr., Chu TM. Characterization of a new primary human pancreatic tumor line. Cancer Invest 1986; 4: 15–23.
  • 37
    Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Oncol 2007; 31: 741–51.
  • 38
    Tutter AV, Fryer CJ, Jones KA. Chromatin-specific regulation of LEF-1-beta-catenin transcription activation and inhibition in vitro. Genes Dev 2001; 15: 3342–54.
  • 39
    Li TWH, Ting JH, Yokoyama NN, Bernstein A, van de Wetering M, Waterman ML. Wnt Activation and Alternative Promoter Repression of LEF1 in Colon Cancer. Mol Cell Biol 2006; 26: 5284–99.
  • 40
    Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence MJ, Holcombe RF, Waterman ML. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001; 28: 53–57.
  • 41
    Kobielak A, Kobielak K, Trzeciak WH. A novel isoform of human lymphoid enhancer-binding factor-1 (LEF-1) gene transcript encodes a protein devoid of HMG domain and nuclear localization signal. Acta Biochim Pol 2001; 48: 221–6.
  • 42
    Gradl D, König A, Wedlich D. Functional diversity of Xenopus lymphoid enhancer factor/T-cell factor transcription factors relies on combinations of activating and repressing elements. J Biol Chem 2002; 277: 14159–71.
  • 43
    van de Wetering M, Castrop J, Korinek V, Clevers H. Extensive alternative splicing and dual promoter usage generate Tcf-1 protein isoforms with differential transcription control properties. Mol Cell Biol 1996; 16: 745–52.
  • 44
    Nishita M, Hashimoto MK, Ogata S, Laurent MN, Ueno N, Shibuya H, Cho KWY. Interaction between Wnt and TGF−β signalling pathways during formation of Spemann's organizer. Nature 2000; 403: 781–85.
  • 45
    Beland M, Pilon N, Houle M, Oh K, Sylvestre JR, Prinos P, Lohnes D. Cdx1 autoregulation is governed by a novel Cdx1-LEF1 transcription complex. Mol Cell Biol 2004; 24: 5028–38.
  • 46
    Yamamoto H, Ihara M, Matsuura Y, Kikuchi A. Sumoylation is involved in β-catenin-dependent activation of Tcf-4. The EMBO Journal 2003; 22: 2047.
  • 47
    Daniels DL, Weis WI. ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol Cell 2002; 10: 573–84.
  • 48
    Waterman ML. Lymphoid enhancer factor/T cell factor expression in colorectal cancer. Cancer Metastasis Rev 2004; 23: 41–52.
  • 49
    Clevers H. Wnt breakers in colon cancer. Cancer Cell 2004; 5: 5–6.
  • 50
    van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der HK, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241–50.
  • 51
    Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005; 24: 2410–20.
  • 52
    Gebeshuber CA, Sladecek S, Grunert S. Beta-catenin/LEF-1 signalling in breast cancer—central players activated by a plethora of inputs. Cells Tissues Organs 2007; 185: 51–60.
  • 53
    Heller RS, Klein T, Ling Z, Heimberg H, Katoh M, Madsen OD, Serup P. Expression of Wnt, Frizzled, sFRP, and DKK genes in adult human pancreas. Gene Expr 2003; 11: 141–7.
  • 54
    Ripka S, König A, Buchholz M, Wagner M, Sipos B, Klöppel G, Downward J, Gress T, Michl P. WNT5A - target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 2007; 28: 1178–87.
  • 55
    Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen Type I Induces Disruption of E-Cadherin-Mediated Cell-Cell Contacts and Promotes Proliferation of Pancreatic Carcinoma Cells. Cancer Res 2006; 66: 4662–71.
View Full Article with Supporting Information (HTML) Get PDF (652K)